2023
MGMT promoter methylation in 1p19q-intact gliomas
Kinslow C, Siegelin M, Iwamoto F, Gallitto M, Neugut A, Yu J, Cheng S, Wang T. MGMT promoter methylation in 1p19q-intact gliomas. Journal Of Neuro-Oncology 2023, 166: 73-78. PMID: 38114801, DOI: 10.1007/s11060-023-04515-z.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseMGMT promoter methylationOverall survivalIDH-wildtypeMGMT statusAdjuvant temozolomideAnaplastic gliomasPromoter methylationAssociated with poor survivalAssociation of MGMTClinical efficacy of temozolomideIDH-mutant astrocytomasCox proportional hazards regression modelsIDH-wildtype gliomasKaplan-Meier methodWell-powered prospective studiesMGMT promoter statusEfficacy of temozolomideProportional hazards regression modelsInternational randomized phaseStandard-of-careHazards regression modelsCATNON trialAnaplastic astrocytomaCancer DatabaseMGMT Promoter Methylation Predicts Survival in 1p19q-Codeleted Gliomas after Chemotherapy
Kinslow C, Rae A, Kumar P, Grinband J, Gill B, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Yu J, Kachnic L, Cheng S, Wang T. MGMT Promoter Methylation Predicts Survival in 1p19q-Codeleted Gliomas after Chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e117. DOI: 10.1016/j.ijrobp.2023.06.902.Peer-Reviewed Original ResearchMGMT promoter methylationMGMT promoter statusMGMT promoter methylation statusAssociated with poor survivalNational Cancer DatabaseOverall survivalUnmethylated MGMTPromoter methylation statusPromoter methylationPromoter statusAlkylating chemotherapyPoor survivalMultivariate Cox proportional hazards regression modelsResponse to alkylating chemotherapyProgression-free survivalCox proportional hazards regression modelsMethylation statusProportional hazards regression modelsReceipt of chemotherapyHazards regression modelsCourse of treatmentAnaplastic gliomasMGMT promoterCancer DatabaseDiagnosed gliomasMGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas.
Kinslow C, Rae A, Taparra K, Kumar P, Siegelin M, Grinband J, Gill B, McKhann G, Sisti M, Bruce J, Canoll P, Iwamoto F, Horowitz D, Kachnic L, Neugut A, Yu J, Cheng S, Wang T. MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas. Clinical Cancer Research 2023, 29: 4399-4407. PMID: 37611077, PMCID: PMC10872921, DOI: 10.1158/1078-0432.ccr-23-1295.Peer-Reviewed Original ResearchConceptsAssociated with worse survivalOverall survivalMGMT promoter statusUnmethylated MGMTWorse survivalPrognostic of progression-free survivalPromoter statusMultivariate Cox proportional hazards regression modelsWorld Health Organization gradeProgression-free survivalNational Cancer DatabaseCox proportional hazards regression modelsMGMT promoter methylationProportional hazards regression modelsGuiding treatment decisionsHazards regression modelsCourse of treatmentPredictive of responseMultiagent chemotherapyMGMT promoterCancer DatabaseMMGMTAlkylating chemotherapyChemotherapyEligible patientsRisk Stratification for Management of Solitary Fibrous Tumor/Hemangiopericytoma of the Central Nervous System
Kinslow C, Rae A, Kumar P, McKhann G, Sisti M, Bruce J, Yu J, Cheng S, Wang T. Risk Stratification for Management of Solitary Fibrous Tumor/Hemangiopericytoma of the Central Nervous System. Cancers 2023, 15: 876. PMID: 36765837, PMCID: PMC9913704, DOI: 10.3390/cancers15030876.Peer-Reviewed Original ResearchNational Cancer DatabaseCause-specific survivalIntermediate-risk groupCentral nervous systemSolitary fibrous tumor/hemangiopericytomaAssociation of radiotherapyHigh-risk groupOverall survivalRisk categoriesRisk stratificationAssociated with improved survivalPrognostic risk categoriesGross-total resectionKaplan-Meier methodNervous systemCox proportional hazards regressionLow-risk groupProportional hazards regressionEORTC Cooperative GroupRadiotherapy strategiesSEER databaseSurvival benefitProspective trialsCancer DatabaseMeningeal tumorsNational Patterns of Early Adoption of Magnetic Resonance Imaging–Guided Linear Accelerators in 2018 to 2019
Yu J, Kinslow C, Cheng S, Ellis R, Horowitz D. National Patterns of Early Adoption of Magnetic Resonance Imaging–Guided Linear Accelerators in 2018 to 2019. Advances In Radiation Oncology 2023, 8: 101167. PMID: 36798607, PMCID: PMC9926207, DOI: 10.1016/j.adro.2022.101167.Peer-Reviewed Original ResearchNational Cancer DatabaseIntensity modulated radiation therapyFood and Drug Administration approvalSite of diseaseImprove radiation treatmentDrug Administration approvalFood and Drug AdministrationSample of patientsRadiation therapyLinear acceleratorCancer DatabaseAdministration approvalDisease sitesRadiation treatmentComprehensive cancer centerAcademic centersCancer CenterDrug AdministrationPatientsPractice patternsTherapyCancer sitesAdapt treatmentImproved visualizationBreast
2022
Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma.
Gao S, Jin L, Moliterno J, Corbin ZA, Bindra RS, Contessa JN, Yu JB, Park HS. Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma. Journal Of Neurosurgery 2022, 138: 610-620. PMID: 35907197, DOI: 10.3171/2022.5.jns212761.Peer-Reviewed Original ResearchConceptsWeeks of biopsyOverall survivalCox proportional hazards regression modelingProportional hazards regression modelingNational Cancer DatabaseInitiation of radiotherapyKaplan-Meier methodWorse overall survivalWilcoxon rank sum testEffects of confoundersRank sum testUnresected diseaseAdjuvant radiotherapyConcurrent chemotherapyMedian intervalMultivariable analysisRadiotherapy delayCancer DatabaseClinical dataBiopsyPatientsLate initiationAggressive natureRadiotherapyPotential association
2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatientsNational Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non-Small Cell Lung Cancer.
Grant S, Smith B, Colbert L, Nguyen Q, Yu J, Lin S, Chen A. National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non-Small Cell Lung Cancer. Journal Of The National Comprehensive Cancer Network 2021, 19: 1-6. PMID: 34044365, DOI: 10.6004/jnccn.2020.7688.Peer-Reviewed Original ResearchNon-small cell lung cancerCell lung cancerMetastatic non-small cell lung cancerTreatment courseLung cancerBone metastasesSite of metastatic diseaseNational Cancer DatabaseYear of diagnosisNational Quality ForumMetastatic diseaseRadiation therapyPalliative radiationCancer DatabaseBone radiationTreatment characteristicsMultivariate analysisTreatment scheduleRate of complianceRecommended scheduleBony sitesPatientsShort courseCancerAcademic facilitiesPrevalence of Missing Data in the National Cancer Database and Association With Overall Survival
Yang DX, Khera R, Miccio JA, Jairam V, Chang E, Yu JB, Park HS, Krumholz HM, Aneja S. Prevalence of Missing Data in the National Cancer Database and Association With Overall Survival. JAMA Network Open 2021, 4: e211793. PMID: 33755165, PMCID: PMC7988369, DOI: 10.1001/jamanetworkopen.2021.1793.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseNon-small cell lung cancerOverall survivalCell lung cancerCancer DatabaseMedical recordsLung cancerProstate cancerBreast cancerPatient recordsComplete dataRetrospective cohort studyCohort studyCancer RegistryCommon cancerVariables of interestHigh prevalenceMAIN OUTCOMEPatientsClinical advancementReal-world data sourcesCancerPrevalenceSurvivalHeterogeneous differences
2020
National trends in the management of patients with positive surgical margins at radical prostatectomy
Ghabili K, Park HS, Yu JB, Sprenkle PC, Kim SP, Nguyen KA, Ma X, Gross CP, Leapman MS. National trends in the management of patients with positive surgical margins at radical prostatectomy. World Journal Of Urology 2020, 39: 1141-1151. PMID: 32562045, DOI: 10.1007/s00345-020-03298-6.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyPositive surgical marginsUse of ADTPost-prostatectomy radiation therapyRadiation therapySurgical marginsRadical prostatectomyInitial courseNode-negative prostate cancerPost-operative radiation therapyMultivariable logistic regression modelNational Cancer DatabaseAdverse pathologic featuresManagement of patientsPost-operative managementLogistic regression modelsDeprivation therapySurgical cancersPrimary endpointRT useSecondary endpointsPathologic characteristicsPathologic featuresUninsured statusCancer DatabaseAssociation of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era.
Miccio J, Ma S, Oladeru O, Yang D, Peters G, Jethwa K, Park H, Hurwitz M, Leapman M, Sprenkle P, Nguyen P, Yu J, Johung K. Association of cytoreductive nephrectomy and survival in the immune checkpoint inhibitor era. Journal Of Clinical Oncology 2020, 38: 748-748. DOI: 10.1200/jco.2020.38.6_suppl.748.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaCytoreductive nephrectomyICI eraImproved overall survivalNational Cancer DatabaseOverall survivalIFN eraFuhrman gradeBenefit of CNEfficacy of ICIsClinical T stageCox regression analysisTreatment facility typeRenal cell carcinomaCARMENA trialInterferon eraMultivariable associateN0 diseaseOS benefitProspective reevaluationMedian ageT stageCell carcinomaCancer DatabasePartial nephrectomy
2018
Defining an Intermediate Risk Group for Low Grade Glioma? An Analysis of the National Cancer Database
Jairam V, Kann B, Park H, Miccio J, Beckta J, Yu J, Gao S, Prabhu R, Mehta M, Curran W, Bindra R, Contessa J, Patel K. Defining an Intermediate Risk Group for Low Grade Glioma? An Analysis of the National Cancer Database. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e249-e250. DOI: 10.1016/j.ijrobp.2018.07.827.Peer-Reviewed Original ResearchImpact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States
Bledsoe T, Park H, Rutter C, Aneja S, Nguyen PL, Yu J. Impact of Health Insurance Status on Prostate Cancer Treatment Modality Selection in the United States. American Journal Of Clinical Oncology 2018, 41: 1062-1068. PMID: 29521648, DOI: 10.1097/coc.0000000000000423.Peer-Reviewed Original ResearchTreatment modality selectionInsurance statusTreatment modalitiesProstate cancerPrivate insuranceProstate cancer treatment modalitiesMultivariable logistic regression analysisInvasive surgeryModality selectionCancer-directed treatmentD'Amico risk classificationTreatment modality choiceNational Cancer DatabaseLocalized prostate cancerPatient insurance statusExternal beam radiotherapyLogistic regression analysisHealth insurance statusStrongest predictorMen ages 18Cancer treatment modalitiesClinical factorsMultivariable analysisActive surveillanceCancer Database
2017
RTHP-16. PATTERNS OF TREATMENT AND OUTCOMES OF 1p19q CO-DELETED GLIOMAS
Yeboa D, Yu J, Huse J, Penas-Prado M, Sulman E, Contessa J. RTHP-16. PATTERNS OF TREATMENT AND OUTCOMES OF 1p19q CO-DELETED GLIOMAS. Neuro-Oncology 2017, 19: vi222-vi222. PMCID: PMC5692027, DOI: 10.1093/neuonc/nox168.900.Peer-Reviewed Original ResearchGrade III tumorsCombined-modality therapyRadiation therapyCox multivariable proportional hazards modelMultivariable proportional hazards modelsNational Cancer DatabasePatterns of treatmentGrade II tumorsPatterns of carePost-operative therapyProportional hazards modelLow-grade gliomasOverall survivalII tumorsHistologic gradeCancer DatabaseTumor gradeGrade IITreatment outcomesAdditional molecular characterizationHazards modelGrade gliomasPatientsTherapyGliomas
2014
Predictors of 30-Day Mortality Following Resection of Early-Stage NSCLC: An Analysis of the National Cancer Database
Husain Z, Kim A, Yu J, Decker R, Corso C. Predictors of 30-Day Mortality Following Resection of Early-Stage NSCLC: An Analysis of the National Cancer Database. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s59. DOI: 10.1016/j.ijrobp.2014.05.205.Peer-Reviewed Original Research